Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To compare the pharmacodynamic properties of two different doses of a new insulin glargine
formulation with 0.4 U/kg Lantus®
Secondary Objective:
To compare the pharmacokinetic properties of two different doses of a new insulin glargine
formulation with 0.4 U/kg Lantus® To assess the safety and tolerability of a new insulin
glargine formulation